Login / Signup

Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail.

Ashish SrinivasanPeter De CruzDaniel R Van Langenberg
Published in: Alimentary pharmacology & therapeutics (2020)
Keyphrases
  • rheumatoid arthritis
  • ulcerative colitis
  • patients with inflammatory bowel disease